As of 2025-04-26, the Intrinsic Value of Protagonist Therapeutics Inc (PTGX) is 76.81 USD. This PTGX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 44.49 USD, the upside of Protagonist Therapeutics Inc is 72.70%.
The range of the Intrinsic Value is 56.20 - 128.04 USD
Based on its market price of 44.49 USD and our intrinsic valuation, Protagonist Therapeutics Inc (PTGX) is undervalued by 72.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 56.20 - 128.04 | 76.81 | 72.7% |
| DCF (Growth 10y) | 66.54 - 143.68 | 88.83 | 99.7% |
| DCF (EBITDA 5y) | 55.00 - 65.66 | 60.15 | 35.2% |
| DCF (EBITDA 10y) | 65.33 - 80.76 | 72.60 | 63.2% |
| Fair Value | 112.08 - 112.08 | 112.08 | 151.93% |
| P/E | 83.84 - 205.61 | 136.47 | 206.7% |
| EV/EBITDA | 46.21 - 190.77 | 94.65 | 112.7% |
| EPV | 3.32 - 3.86 | 3.59 | -91.9% |
| DDM - Stable | 32.26 - 94.30 | 63.28 | 42.2% |
| DDM - Multi | 27.93 - 66.41 | 39.67 | -10.8% |
| Market Cap (mil) | 2,730.80 |
| Beta | 0.51 |
| Outstanding shares (mil) | 61.38 |
| Enterprise Value (mil) | 2,633.55 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.00% |
| Cost of Debt | 5.00% |
| WACC | 6.34% |